Clinical trials
Our mission is to accelerate the development of stem cell research and treatments. We will therefore sponsor and support clinical trials starting in the first half of 2023.
Realizing the potential
Studies have shown that mesenchymal stromal cells (a type of stem cells) reduce inflammation, modulate the immune system, and regenerate damaged or diseased tissues, promoting better health and quality of life. This makes them an ideal candidate to tackle a number of chronic diseases where there is currently no good other option.
Cellcolabs was founded to solve the problem of poor availability and high prices of high-quality stem cells for research and treatments. We build on the findings and clinical experience from more than 20 years of stem cell research at Karolinska Institutet, including 167 published scientific papers with 30 000 citations (as of 2021), resulting in exceptional stem cell quality. Our cells are mesenchymal stromal cells (MSCs) derived from the bone marrow of healthy young donors, and have previously been approved by the Swedish Medical Products Agency for use in two academic clinical trials. Our next step is to sponsor larger scale international trials.
Current Clinical Trials
As with most other stem cell products, our stem cells are considered an investigational medicinal product, as there is no market approval yet. The underlying mechanism of stem cell treatment still remains unclear and more data and research is needed. This is why an important part of Cellcolabs' work is to drive scale in clinical trials.
Cellcolabs' cells will be used in international clinical trials for various conditions, including Ageing Frailty, Osteoarthrosis (OA), and other cognitive impairments and orthopedic conditions.
Our Clinical Partners
Our Stem Cells
Participation Process
Connect with us!
If you would like to learn more about our clinical trials, please fill out the form below or email info@cellcolabs.com and we will be in touch. We will do our best to answer your questions.